ZIOPHARM Oncology (ZIOP) Stock Price, News & Analysis

Company Overview

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.82 to $1.39
• 52-Week Range: N/A
• Volume: 2.13 million shs
• Average Volume: 2.01 million shs
• Market Capitalization: $187.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ZIOP Stock Analysis - Frequently Asked Questions

How were ZIOPHARM Oncology's earnings last quarter?

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) released its earnings results on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.04. The biotechnology company earned $0.40 million during the quarter.

What other stocks do shareholders of ZIOPHARM Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ZIOPHARM Oncology investors own include Precigen (PGEN), Bristol Myers Squibb (BMY), OPKO Health (OPK), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Amarin (AMRN) and CorMedix (CRMD).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 7/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ZIOP
• CIK: 1107421
• Web: www.ziopharm.com
• Phone: (617) 259-1970
• Fax: 617-241-2855
• Employees: 105
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): ($0.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$79.98 million
• Net Margins: N/A
• Pretax Margin: -22,544.97%
• Return on Equity: -92.84%
• Return on Assets: -72.46%

Debt

• Debt-to-Equity Ratio: 0.18
• Current Ratio: 3.43
• Quick Ratio: 3.43

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.58 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 216,146,000
• Free Float: 204,906,000
• Market Cap: $187.12 million
• Optionable: Optionable
• Beta: 1.71